88P Evaluation of trending drug targets and technologies in current drug development

Novel investigational agents (IAs) aim to exploit new mechanisms and cancer vulnerabilities, expanding our arsenal of anticancer drugs. Recently, highly selective biomarker-directed IAs have allowed advancements in the precision treatment oncogene-driven cancers by decreasing toxicity increasing activity. In phase I drug development, a global problem unknown magnitude is multiplicity similar drugs being investigated against same target, colloquially known as ‘me too’ phenomenon. The Clinicaltrials.gov online database was queried for clinical trials active during two-year timeframe from December 2020 2022. Natural language processing employed extract experimental interventions. Autoritative sources (Cancer.gov, Pubmed, et similia) were classify based on target class/structure. Whenever data unavailable these websites, lower tier employed. Overall frequency co-occurrence analyses subsequently evaluated. By surveying current landscape (December 2022), we identified 4480 distinct IAs. Excluding without direct mechanistic targets, non-human genome encoded targets (such viral proteins, metabolites, carbohydrates or undisclosed data, 1016 gene 3495 identified. While only minority had 4 more directed them (26.7%) majority IA, 83.3% single-target 92.5% multi-targeted, this targets. most frequent IA classes Inhibitors(1105), Cell products(933), Monospecific-monoclonal antibodies(488) Vaccines(252). number were: CD19(316), EGFR(131), CD3(126), ERBB2(125), BCMA(108) PD-1(106), CTLA4-PD1 PDL1-CTLA4 cooccurring pairs. Only (9.3%) explored competitive agent; Unfortunately, (86%) shared with at least 3 other agents. We argue that duplicative efforts could be redirected toward unmet needs instead.